Jeffrey Crawford

Dr. Jeffrey Crawford

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2004 in Cancer
Verified
Journal Article
Closed access
PDF file
JCJeffrey Crawford
Jeffrey Crawford
DDDavid C. Dale
David C. Dale
GLGary H. Lyman
Gary H. Lyman

11 May 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
CNCarrie M. Nielson
Carrie M. Nielson
LBLauren C Bylsma
Lauren C Bylsma
JFJon P. Fryzek
Jon P. Fryzek
HSHossam A. Saad
Hossam A. Saad
JCJeffrey Crawford
Jeffrey Crawford
Background Chemotherapy‐induced toxicities lead to therapy dose reduction or delay affecting patient outcomes. This systematic review and meta‐analysis evaluated the impact of relative dose intensity (RDI) on survival in adult solid‐tumor cancer patients on nonadjuvant‐based chemotherapy regimens. Methods PubMed, Embase, and Web of Science databases were searched for peer‐reviewed English journal articles or congress abstracts evaluating association between RDI and survival; observational studies, case series of ≥20 patients, and clinical trials published between 2013─2020 were eligible. Meta‐analyses were conducted to quantify the association between RDI levels and overall survival (OS) among studies reporting a hazard ratio (HR) for OS by similar tumor types, regimens, and RDI. Forest plots represented summary HR and 95% confidence interval (CI); Cochran's Q and I2 tests evaluated study heterogeneity. Results Overall, 914 articles were reviewed and 37 included; seven were eligible for meta‐analysis. Significantly shorter OS at RDI <80 vs ≥80% and <85% vs ≥85% was observed upon meta‐analysis of four carboplatin‐based studies for breast, non‐small cell lung, or ovarian cancer (HR 1.17; 95% CI: 1.07–1.27), and three FOLFOX‐/FOLFIRI/FOLFIRINOX‐based studies for colorectal or pancreatic cancer (HR 1.39; 95% CI: 1.03–1.89). Grade 3 or higher hematologic toxicities were higher for carboplatin‐based regimens (thrombocytopenia: 14–22%; anemia: 15–19%; neutropenia: 24–58%) than FOLFOX‐/FOLFIRI/FOLFIRINOX‐based regimens (thrombocytopenia: 1–4%; anemia: 5–19%; neutropenia: 19–47%). Conclusion The results suggested longer OS with RDI ≥80 or ≥85% for both regimens, indicating that management of toxicities across treatment modalities may contribute to maintenance of higher RDI and benefit survival for patients with advanced solid tumors. Implications for Practice Chemotherapy‐induced toxicities lead to dose reduction and/or treatment delay , thus affecting patient outcomes. Results of this systematic review and meta‐analysis, evaluating the impact of relative dose intensity (RDI) on survival in solid tumor cancer patients on nonadjuvant‐based chemotherapy regimens, demonstrate a longer overall survival with RDI levels of at least 80% for solid tumor cancer patients on carboplatin‐based and FOLFOX‐/FOLFIRI/FOLFIRINOX‐based chemotherapy regimens, suggesting a protective effect of maintaining RDI ≥80 or ≥85%. While grade 3 or higher hematologic toxicities occurred more in carboplatin‐based studies, managing toxicities across treatment regimens may contribute to maintenance of higher RDI and ultimately benefit overall survival.

2 May 2016 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
JCJeffrey Crawford
Jeffrey Crawford
CPCarla M. M. Prado
Carla M. M. Prado
MJMary Ann Johnston
Mary Ann Johnston
RGRichard J. Gralla
Richard J. Gralla
RTRyan P. Taylor
Ryan P. Taylor
JDJames T Dalton
James T Dalton
Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive functional impairment, decreased quality of life, and increased mortality. Although several therapeutic agents are currently in development for the treatment of muscle wasting or cachexia in cancer, the majority of these agents do not directly inhibit muscle loss. Selective androgen receptor modulators (SARMs) have the potential to increase lean body mass (LBM) and hence muscle mass, without the untoward side effects seen with traditional anabolic agents. Enobosarm, a nonsteroidal SARM, is an agent in clinical development for prevention and treatment of muscle wasting in patients with cancer (POWER 1 and 2 trials). The POWER trials are two identically designed randomized, double-blind, placebo-controlled, multicenter, and multinational phase 3 trials to assess the efficacy of enobosarm for the prevention and treatment of muscle wasting in subjects initiating first-line chemotherapy for non-small-cell lung cancer (NSCLC). To assess enobosarm’s effect on both prevention and treatment of muscle wasting, no minimum weight loss is required. These pivotal trials have pioneered the methodological and regulatory fields exploring a therapeutic agent for cancer-associated muscle wasting, a process hereby described. In each POWER trial, subjects will receive placebo (n = 150) or enobosarm 3 mg (n = 150) orally once daily for 147 days. Physical function, assessed as stair climb power (SCP), and LBM, assessed by dual-energy X-ray absorptiometry (DXA), are the co-primary efficacy endpoints in both trials assessed at day 84. Based on extensive feedback from the US Food and Drug Administration (FDA), the co-primary endpoints will be analyzed as a responder analysis. To be considered a physical function responder, a subject must have ≥10 % improvement in physical function compared to baseline. To meet the definition of response on LBM, a subject must have demonstrated no loss of LBM compared with baseline. Secondary endpoints include durability of response assessed at day 147 in those responding at day 84. A combined overall survival analysis for both studies is considered a key secondary safety endpoint. The POWER trials design was established with extensive clinical input and collaboration with regulatory agencies. The efficacy endpoints are a result of this feedback and discussion of the threshold for clinical benefit in patients at risk for muscle wasting. Full results from these studies will soon be published and will further guide the development of future anabolic trials. Clinical Trial ID: NCT01355484. https://clinicaltrials.gov/ct2/show/NCT01355484, NCT01355497. https://clinicaltrials.gov/ct2/show/NCT01355497?term=g300505&rank=1.

1 March 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
LHLaura J. Havrilesky
Laura J. Havrilesky
MRMaureen Reiner
Maureen Reiner
PMPhuong Khanh Morrow
Phuong Khanh Morrow
HWHolly Watson
Holly Watson
JCJeffrey Crawford
Jeffrey Crawford

8 April 2024 in Future Oncology
Verified
Journal Article
Open access
JCJeffrey Crawford
Jeffrey Crawford
DHDana Herndon
Dana Herndon
KGKaterina Gmitter
Katerina Gmitter
JWJared Weiss
Jared Weiss
Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fa... Plain language summary Chemotherapy can cause side effects by killing blood-forming cells in the bone marrow. This is known as myelosuppression and leads to neutropenia (decreased neutrophils [whit... Tweetable abstract The burden of chemotherapy-induced myelosuppression on patients with cancer is substantial. We provide insights on the impact of this side effect on the lives of patients and rev...

20 November 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JCJeffrey Crawford
Jeffrey Crawford
RCRoberto A. Calle
Roberto A. Calle
SCSusie M. Collins
Susie M. Collins
YWYan Weng
Yan Weng
SLShannon L. Lubaczewski
Shannon L. Lubaczewski
JRJames H. Revkin
James H. Revkin
Purpose: Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, in adults with advanced cancer, cachexia, and elevated GDF-15 serum concentration. Patients and Methods: Participants (n = 10) received open-label ponsegromab subcutaneous 200 mg every 3 weeks for 12 weeks in addition to standard-of-care anticancer treatment. Ponsegromab safety, tolerability, and pharmacokinetics were assessed in addition to serum GDF-15 concentrations and exploratory measures of efficacy. Results: No treatment-related treatment-emergent adverse events, injection site reactions, or adverse trends in clinical laboratory tests, vital signs, or electrocardiogram parameters attributable to ponsegromab were identified. Median serum unbound GDF-15 concentration at baseline was 2.269 ng/mL. Following initiation of study treatment, median unbound GDF-15 concentrations were below the lower limit of quantification (0.0424 ng/mL) from day 1 (3 hours postdose) through week 15. Increases in body weight were observed at all time points during the treatment and follow-up periods. A least-squares mean (SE) increase of 4.63 (1.98) kg was observed at week 12, an increase of approximately 6.6% relative to baseline. Ponsegromab-mediated improvements in actigraphy-based assessments of physical activity and in quality of life, including appetite as assessed by Functional Assessment of Anorexia-Cachexia Therapy total and subscale scores, were also observed. Conclusions: Ponsegromab was well tolerated, suppressed serum GDF-15 concentrations, and demonstrated preliminary evidence of efficacy. These findings support the continued development of ponsegromab for the treatment of cachexia.